Dulaglutide is an effective treatment for lowering HbA1c in patients with type 2 diabetes regardless of body mass index-Reference-Cited by-同舟云学术

Dulaglutide is an effective treatment for lowering HbA1c in patients with type 2 diabetes regardless of body mass index

Published:2019-08-28 Issue:12 Volume:21 Page:2660-2666
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:Diabetes Obes Metab

Author:

Gentilella Raffaella¹,Sesti Giorgio²,Vazquez Luis³,Sapin Hélène⁴,Reed Victoria⁵^ORCID,Romera Irene⁶,Pozzilli Paolo⁷

Affiliation:

1. Eli Lilly Italia S.p.A. Sesto Fiorentino Italy

2. Department of Clinical and Surgical ScienceUniversity Magna Graecia of Catanzaro Catanzaro Italy

3. Hospital Marqués de ValdecillaUniversidad de Cantabria Santander Spain

4. Lilly France Neuilly‐sur‐Seine France

5. Eli Lilly Windlesham UK

6. Lilly S.A. Alcobendas Spain

7. Department of Endocrinology & DiabetesUniversity Campus Bio‐Medico Rome Italy

Funder

Eli Lilly and Company

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/dom.13853

Reference22 articles.

1. Predictors of efficacy of GLP-1 agonists and DPP-4 inhibitors: A systematic review

2. Correlation Between Baseline Characteristics and Clinical Outcomes in a Large Population of Diabetes Patients Treated with Liraglutide in a Real-World Setting in Italy

3. Predictors of treatment response to liraglutide in type 2 diabetes in a real-world setting

4. Relationship of body mass index with efficacy of exenatide twice daily added to insulin glargine in patients with type 2 diabetes

5. DuránS TinahonesF JódarE et al. Effect of once‐weekly dulaglutide on glycaemic control in patients with type 2 diabetes mellitus and body mass index <30 kg/m2or ≥30 kg/m2. Paper presented at 56 Congreso SEEN (Sociedad Española de Endocrinología y Nutrición) 2014; Valencia Spain.

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparing Efficacy and Safety of Glucagon-Like Peptide 1 (GLP-1) Agonist Versus Sodium-Glucose Cotransporter 2 (SGLT-2) Inhibitors in Chinese Patients with Type 2 Diabetes Mellitus: A Preliminary Study;International Journal of Pharmacology;2024-05-01

2. GLP-1RA may have varying effects on cardiac structure in patients with ASCVD depending on BMI;Frontiers in Endocrinology;2024-03-15

3. Assessment of Changes in Body Composition After 3 Months of Dulaglutide Treatment;Diabetes, Metabolic Syndrome and Obesity;2024-03

4. Predictors of efficacy of Sodium‐GLucose Transporter‐2 inhibitors and Glucagon‐Like Peptide 1 receptor agonists: A retrospective cohort study;Diabetes/Metabolism Research and Reviews;2023-09-30

5. Durability of glucose-lowering effect of dulaglutide in patients with type 2 diabetes mellitus: A real-world data study;Frontiers in Endocrinology;2022-10-31